Lightlake Therapeutics Inc. Set to Begin Phase II Clinical Trials of Binge Eating Disorder Treatment
24 August 2011 - 4:06PM
Business Wire
Lightlake Therapeutics Inc. (OTCBB: LLTP) (“Lightlake” or “the
“Company”), an early stage biopharmaceutical company currently
developing a nasal spray for the treatment of overweight and obese
patients with Binge Eating Disorder, today announced that its
patient testing stage of the Phase II clinical trials will start
August 26th, 2011
Dr. Roger Crystal, CEO of Lightlake commented, “We are excited
to commence the definitive stage of testing of a product that we
believe will be a solution to a disease thought to affect a
significant proportion of obese and overweight patients today. We
recently completed stability testing in an effort to ensure that
our nasal spray adheres to internationally recognised safety
standards in delivering an effective treatment. Moreover, we have
an excellent control group in place, as we were able to select 138
patients from over 900 applicants wanting to participate in our
trials in Helsinki. Dr. David Sinclair, our Chief Scientific
Officer, revolutionized the way we treat alcoholism and drug
addiction through his research into opioid antagonists, and we are
confident that in working with him, we can develop an opioid
antagonist derived nasal spray for the treatment of those with
Binge Eating Disorder.”
In addition to treating patients with Binge Eating Disorder,
Lightlake believes its nasal spray could also beneficial for those
with bingeing behaviour, which is thought to exist in one third of
obese patients. The Company projects that its Phase II trials will
be completed early next year and if successful, Lightlake plans to
conduct its Phase III at Imperial College London and other
international institutions. The Company will work with Celesio AG
to develop a pharmacist delivered treatment program, and intends to
establish similar commercial relationships over the next 12
months.
About Lightlake Therapeutics Inc.
Lightlake Therapeutics is a developing biopharmaceutical company
aiming to build a platform of biopharmaceutical solutions to common
addictive disorders. Currently, the Company is focused on providing
a safe, effective and simple treatment for patients who are obese
or overweight as a result of binge eating. Lightlake recently
acquired patents that will allow it to widen its product pipeline
to address patients with addictions to opioid
painkillers, methadone, cocaine and amphetamine. The Company
anticipates launching a development program for each of these
purposes in the future.
Safe Harbor
This press release contains forward-looking statements. These
statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and
other factors that may cause our or our industry's actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance
or achievements expressed, implied or inferred by these
forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based
on our current expectations and projections about future events.
You should not place undue reliance on these statements. Actual
events or results may differ materially. In evaluating these
statements, you should specifically consider various factors. These
and other factors may cause our actual results to differ materially
from any forward- looking statement. We undertake no
obligation to update any of the forward-looking statements after
the date of this presentation to conform those statements to
reflect the occurrence of unanticipated events, except as required
by applicable law.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024